open access

Vol 78, No 3 (2010)
REVIEWS
Published online: 2010-05-11
Submitted: 2013-02-22
Get Citation

Efficacy and safety of indacaterol - new long-acting β2 agonist

Ryszarda Chazan
Pneumonol Alergol Pol 2010;78(3):229-235.

open access

Vol 78, No 3 (2010)
REVIEWS
Published online: 2010-05-11
Submitted: 2013-02-22

Abstract

Combination of ICS and LABA for asthmatics and several classes of long-acting bronchodilator drugs for COPD patients are recommended. Long-acting bronchodilator therapy should be always considered when patients are symptomatic.
Incorporation of once daily dose administration is an important strategy to improve adherence and is the method preferred by most patients. Several trials evaluated the efficacy and safety of indacaterol in patients with asthma and COPD. The results of the study suggested that indacaterol has a wide therapeutic index and is safe and well tolerated.

Abstract

Combination of ICS and LABA for asthmatics and several classes of long-acting bronchodilator drugs for COPD patients are recommended. Long-acting bronchodilator therapy should be always considered when patients are symptomatic.
Incorporation of once daily dose administration is an important strategy to improve adherence and is the method preferred by most patients. Several trials evaluated the efficacy and safety of indacaterol in patients with asthma and COPD. The results of the study suggested that indacaterol has a wide therapeutic index and is safe and well tolerated.
Get Citation

Keywords

bronchodilators; chronic obstructive pulmonary disease; asthma; indacaterol

About this article
Title

Efficacy and safety of indacaterol - new long-acting β2 agonist

Journal

Advances in Respiratory Medicine

Issue

Vol 78, No 3 (2010)

Pages

229-235

Published online

2010-05-11

Bibliographic record

Pneumonol Alergol Pol 2010;78(3):229-235.

Keywords

bronchodilators
chronic obstructive pulmonary disease
asthma
indacaterol

Authors

Ryszarda Chazan

References (40)
  1. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008; 31(1): 143–178.
  2. Rabe KF, Hurd S, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176(6): 532–555.
  3. Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med. 2004; 140(10): 802–813.
  4. Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006; 144(12): 904–912.
  5. Rodrigo GJ, Moral VP, Marcos LG, et al. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Ther. 2009; 22(1): 9–29.
  6. Walters JAE, Wood-Baker R, Walters EH. Long-acting beta2-agonists in asthma: an overview of Cochrane systematic reviews. Respir Med. 2005; 99(4): 384–395.
  7. Cazzola M, Matera M. The effective treatment of COPD: Anticholinergics and what else? Drug Discovery Today: Therapeutic Strategies. 2006; 3(3): 277–286.
  8. Wise RA, Tashkin DP. Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies. Am J Med. 2007; 120(8 Suppl 1): S4–13.
  9. Aaron SD, Vandemheen KL, Fergusson D, et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007; 146(8): 545–555.
  10. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008; 155(3): 291–299.
  11. Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther. 2006; 317(2): 762–770.
  12. Sturton RG, Trifilieff A, Nicholson AG, et al. Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther. 2008; 324(1): 270–275.
  13. Naline E, Trifilieff A, Fairhurst RA, et al. Effect of indacaterol, a novel long-acting  2-agonist, on isolated human bronchi. European Respiratory Journal. 2007; 29(3): 575–581.
  14. Khindri S, Sabo R, Harris S, et al. Cardiac safety of indacaterol — no clinical effect on QT interval in healthy subjects. Eur Respir J. 2009; 34(supl. 53): P2031.
  15. Bauwens O, Ninane V, Van de Maele B, et al. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin. 2009; 25(2): 463–470.
  16. Beeh KM, Derom E, Kanniess F, et al. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J. 2007; 29(5): 871–878.
  17. La Fo, Alexander M, Deckelmann R. Indacaterol provides sustained 24h bronchodilatation on once daily dosing in asthma a 7-day dose-ranging study. Allergy. 2008; 63: 203–211.
  18. Brookman LJ, Knowles LJ, Barbier M, et al. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. Curr Med Res Opin. 2007; 23(12): 3113–3122.
  19. LaForce C, Korenblat P, Osborne P, et al. 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol. Curr Med Res Opin. 2009; 25(10): 2353–2359.
  20. Kanniess F, Boulet LP, Pierzchala W, et al. Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study. J Asthma. 2008; 45(10): 887–892.
  21. Balint B, Watz H, Amos C, et al. on behalf of the INSURE study investigators. Fast onset of bronchodilation with indacaterol in patients with COPD. Eur Respir J. 2009; 34(supl. 53): E4363.
  22. Beier J, Chanez P, Martinot JB, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther. 2007; 20(6): 740–749.
  23. Feldman G, Siler T, Prasad N, et al. INLIGHT 1 study group. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010; 10: 11.
  24. Chung KF, Kornmann O, ack D, et al. on behalf of the INVOLVE study investigators. Safety and tolerability of indacaterol over 52-week of treatment in COPD. Eur Respir J. 2009; 34(supl. 53): E4359.
  25. Beier J, Beeh KM, Pascoe L, et al. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Therapeutics. 2009; 1: 1–5.
  26. Beeh KM, Khindri S, Drollmann AF. Effect of indacaterol maleate on dynamic hyperinflation in patients with COPD. Eur Respir J. 2009; 34(supl. 53): E4357.
  27. Buhl R, Pieters W, ack D, et al. on behalf of the INVOLVE study investigators. Indacaterol once-daily improves dyspnea and BODE index in COPD patients: a 52-week study versus twice-daily formoterol. Eur Respir J. 2009; 34(supl. 53): P2026.
  28. Nonikov V, Verkindre Ch, ack D, et al. on behalf of the INVOLVE study investigators. Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation versus placebo and formoterol. Eur Respir J. 2009; 34(supl. 53): P2024.
  29. Dahl R, Kolman P, ack D, et al. on behalf of the INVOLVE study investigators. Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol. Eur Respir J. 2009; 34(supl. 53): E4350.
  30. Magnussen H, Paggiaro P, ack D, et al. on behalf of the INVOLVE study investigators. Indacaterol once-daily improves health-related quality of life (HRQoL) in COPD patients: a 52-week study versus placebo and formoterol. Eur Respir J. 2009; 34(supl. 53): P2019.
  31. Magnussen H., Verkindre H., Jack D. i wsp. on behalf of the INPUT study investigator. Indacaterol once-daily is equally effective dosed either in the evening and morning in COPD patients: a placebo controlled comparison with salmeterol. Vienna, 12-16.09.2009.
  32. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med. 2008; 102(7): 1033–1044.
  33. Fogarty Ch, Iqbal A, Owen R, et al. on behalf of the INHANCE study investigators. Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation versus placebo and tiotropium. Eur Respir J. 2009; 34(supl. 53): P2025.
  34. Cosio BG, Iqbal A, et al. on behalf of the INHANCE study investigators. Indacaterol once-daily improves day and night--time symptom control in COPD patients: a 26-week study versus placebo and tiotropium. Eur Respir J. 2009; 34(supl. 53): P2029.
  35. Mahler DA, Palange P, Iqbal A, et al. on behalf of the INHANCE study investigators. Indacaterol once-daily improves dyspnea in COPD patients: a 26-week placebo-controlled study with open label tiotropium comparison. Eur Respir J. 2009; 34(supl. 53): E4360.
  36. Yorgancioglu A, Mahler DA, Iqbal A, et al. on behalf of the INHANCE study investigators. Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium. Eur Respir J. 2009; 34(supl. 53): P2028.
  37. Worth H, Kleerup E, Iqbal A, et al. on behalf of the INHANCE study investigators. Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study. Eur Respir J. 2009; 34(supl. 53): P2030.
  38. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med. 2008; 102(7): 1033–1044.
  39. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008; 155(3): 291–299.
  40. Roig J, Hernando R, Mora R. Indacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist. Open Respir Med J. 2009; 3: 27–30.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl